Virtual Library
Start Your Search
Y. Chen
Author of
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-095 - Intensity Expression of DOK2 as a Prognostic Marker in Patients with Advanced Stage of Lung Adenocarcinoma (ID 1199)
09:30 - 09:30 | Author(s): Y. Chen
- Abstract
Background:
DOK family is an adaptor proteins that function in feedback loops to modulate tyrosine kinase signaling, including epidermal growth factor receptor, c-Kit and platelet-derived growth factor receptor. Our previous study has shown that DOK2 was up-regulated in PBMC of NSCLC patients, and partially reversed after chemotherapy. We speculated that DOK2 levels in tumor tissue may be used to predict outcome of non-small cell lung cancer. The aim of this study is to determine the significance of DOK2 in advanced stage of lung adenocarcinoma.
Methods:
We retrospectively reviewed the data of 87 advanced stage of lung adenocarcinoma patients from Kaohsiung Chang Gung Memorial Hospital, Taiwan between Jan 2008 and Dec 2009. Tumor tissue was analyzed for DOK2 protein expressions detected via immunohistochemistry and specimens were classified into high or low DOK2 expression groups. Correlation with survival and clinicopathological parameters were undertaken.
Results:
DOK2 expression was confirmed in the advanced stage of lung adenocarcinoma tissue. Considerable differences in the protein expression were noted among the lung adenocarcinoma tissue. Patients were classified to high intensity DOK2 stained expression (n=53, 60.9%) or low intensity stained DOK2 expression (n=34, 39.1%), There were no significant correlation was found between DOK2 expression and clinicopathologic factor such as TNM stage, tumor size, performance status, comorbidity and treatment. Patients with low intensity DOK2 expression were significant and independent determinants of poor progressive free survival (9.5ms vs 4.3ms, P= 0.018) and overall survival (19.9ms vs 6.8ms, P= 0.013).
Conclusion:
Our study suggests the potential usefulness of DOK2 as a clinical marker for evaluating the advanced stage of lung adenocarcinoma progression and prognostic value. Prospective survey and mechanism studies are needed for further confirmation.
